Document Detail


Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013.
MedLine Citation:
PMID:  23456407     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
PURPOSE: Factors likely to influence drug expenditures, drug expenditure trends in 2012, and projected drug expenditures for U.S. nonfederal hospitals and clinics in 2013 are discussed.
METHODS: Prescription drug expenditure data for 2011 through September 2012 were obtained from the IMS Health National Sales Perspectives database. Expenditure projections were based on a combination of quantitative and qualitative analyses, combined with expert opinion.
RESULTS: Total prescription sales in the United States for the 12-month period ending September 2012 were $326.0 billion, a 0.8% increase from the previous 12 months. This rate of growth was the lowest in recent history and can be attributed to modest increases in expenditures for new products (3.3%) and the prices of existing products (5.9%), coupled with a marked decline in overall volume and mix (-8.4%). For the 9 months ending in September 2012, total prescription expenditures grew 2.7% when compared with the same period in 2011. Oncology products remained important expenditures for hospitals and clinics. Antineoplastic agents were the top medication class for expenditures in nonfederal hospitals, and oncology products accounted for 32.2% of drug expenditures in the clinic setting in the first 9 months of 2012.
CONCLUSION: For 2013, we project a 1-3% increase in total drug expenditures across all settings, a 2-4% increase in expenditures for clinic-administered drugs, and a 0.5% decline to 1.5% increase in hospital drug expenditures. Health-system pharmacy leaders should carefully examine their own local drug-utilization patterns to determine their own organization's drug expenditure forecast. AM J HEALTH-SYST PHARM.: 2013; 70:525-39.
Authors:
James M Hoffman; Edward Li; Fred Doloresco; Linda Matusiak; Robert J Hunkler; Nilay D Shah; Lee C Vermeulen; Glen T Schumock
Related Documents :
18829477 - The use of genomics in clinical trial design.
12830927 - The role of peptides in treatment of psychiatric disorders.
20678007 - Topological properties of the drug targets regulated by microrna in human protein-prote...
21077637 - Molecular topology analysis of the differences between drugs, clinical candidate compou...
19889017 - Using the internet to recruit patients for epilepsy trials: results of a new zealand pi...
8637937 - Current trends in cardiovascular pharmacology.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  70     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  525-39     Citation Subset:  IM    
Affiliation:
James M. Hoffman, Pharm.D., M.S., BCPS, is Associate Member, Pharmaceutical Sciences, Medication Outcomes and Safety Officer, Pharmaceutical Services, St. Jude Children's Research Hospital, Memphis, TN, and Associate Professor of Clinical Pharmacy, College of Pharmacy, University of Tennessee Health Science Center, Memphis.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simu...
Next Document:  Implementing standardized intravenous antibiotic desensitizations among hospital inpatients.